Shenqi Medical

Established in 2014 by founder Dai Zhihao, Shenqi Medical is a medical device company headquartered in Shanghai, China, that has reached the Series C funding stage. The firm operates within the cardiovascular and neurovascular intervention markets, focusing on the research, development, manufacturing, and sales of its devices. Shenqi Medical's business is centered on providing advanced solutions for cardiovascular surgeries. The company has successfully secured significant investment, including a Series C funding round of $14.4 million on August 24, 2020, led by Hillhouse and LYFE Capital, bringing its total raised capital to $14.4 million from six institutional investors.

The company’s product portfolio addresses critical needs in cardiac and vascular procedures. A key product is the Swide® Qiji® drug-coated coronary balloon catheter, which received registration as a Class III medical device in December 2019 and is now utilized in over 1,100 hospitals across China. Another significant offering is the SQ-Kyrin® Shen Qiqilin® transcatheter mitral valve clip and its accompanying steerable guide catheter, which entered the national fast-track approval channel for innovative medical devices in August 2021. In January 2022, the company also obtained registration for its SQ-WindRider® Qiyi® detachable coil embolization system for peripheral vascular interventions. Through its affiliated company, Beijing Hatekaier Medical Technology, Shenqi Medical is also involved in developing ultrafiltration treatment equipment for heart failure. The company holds numerous patents for its self-developed products, including a tricuspid valve repair device and a delivery device for spring coils.

Shenqi Medical's strategy is focused on providing a comprehensive suite of solutions for treating cardiovascular diseases. The company’s products are designed to support minimally invasive procedures, aiming for safer and more reliable surgical outcomes. Its revenue generation is based on the sale of these specialized medical devices to hospitals and other healthcare facilities. The firm is actively engaged in clinical trials to validate the safety and effectiveness of its new products, such as the transcatheter mitral valve clip system for patients with functional mitral regurgitation. With a portfolio of 2 commercialized products and 33 more in the development pipeline, Shenqi Medical is positioned to address the growing healthcare demands within the Chinese market and beyond. Keywords: cardiovascular devices, interventional cardiology, medical technology, Shanghai, Dai Zhihao, drug-coated balloon, transcatheter mitral valve repair, embolization coils, heart failure treatment, minimally invasive surgery, vascular intervention, neurovascular devices, medical device manufacturing, Hillhouse Capital, LYFE Capital, Class III medical device, coronary artery disease, structural heart disease, peripheral artery disease, clinical trials